AI Accurate in Diagnosing Suspicious Skin Lesions
By Lori Solomon HealthDay Reporter
WEDNESDAY, Nov. 29, 2023 -- A mobile phone-powered artificial intelligence (AI) technology is effective for diagnosing suspicious skin lesions, according to a study published in the October issue of The Lancet Digital Health.
Scott W. Menzies, Ph.D., from the University of Sydney, and colleagues compared the accuracy of AI algorithms and clinicians for the diagnosis and management of pigmented skin lesions. For the diagnostic study, the analysis included 172 suspicious pigmented lesions from 124 patients, while the management study included 5,696 pigmented lesions from 66 high-risk patients.
The researchers found that the diagnoses of the seven-class AI algorithm were similar to the specialists' diagnoses (absolute accuracy difference, 1.2 percent) and significantly superior to the novice clinicians' diagnoses (21.5 percent). Diagnoses based on the International Skin Imaging Collaboration AI algorithm were significantly inferior to the specialists' diagnoses (–11.6 percent) but significantly superior to the novices' diagnoses (8.7 percent). The best seven-class management AI was significantly worse than specialists' management (absolute accuracy difference in correct management decision, –0.5 percent for dismissal and –0.4 percent for biopsy). For novice clinicians' management, the seven-class management AI was significantly inferior (–0.4 percent for dismissal), but significantly superior (0.4 percent) for biopsy.
"An AI algorithm that was superior in experimental studies was significantly inferior to specialists in a real-world scenario, suggesting that caution is needed when extrapolating results of experimental studies to clinical practice," the authors write.
The study was funded by MetaOptima Technology.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Delayed Melanoma Care During Pandemic Proved Costly
TUESDAY, Feb. 27, 2024 -- Delays in melanoma diagnoses due to COVID-19 pandemic lockdowns were associated with a significant burden, including years of life lost and costs...
Amtagvi Approved by the FDA for Treatment of Advanced Melanoma
TUESDAY, Feb. 20, 2024 -- Amtagvi (lifileucel) has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Amtagvi becomes the first...
Smoking Linked to Melanoma-Associated Death in Early-Stage Melanoma
MONDAY, Feb. 12, 2024 -- For patients with clinical stage I and II melanoma, smoking is associated with an increased risk for melanoma-associated death, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.